Étiquette : cannabinoïde

Cannabis, Robert Hämmig, Ulrich W. Preuss und Michael Soyka, 2019

Cannabis  Robert Hämmig, Ulrich W. Preuss und Michael Soyka  January 2019 DOI: 10.1016/B978-3-437-23021-9.00009-6    Kernaussagen  ● Die Cannabispflanze, welche die Menschheit seit Jahrtausenden begleitet, wird vi elfältig genutzt:  ○ als Lieferant für Fasern zur Herstellung von Tüchern, Schnüren, Seilen und Papier,  ○ als Nahrungsmittel (Samenkörner und Öl),  ○ als Medizin für Mensch und Tier sowie als Genussmittel.  ● Im 19. Jh. hielt Cannabis Einzug in die moderne westliche Medizin und wurde auch als „Freizeitdroge“ genutzt. Aus dieser Zeit stammen detaillierte phänomenologische Bes chreibungen der Effekte. Noch blieb aber der Wirkmechanismus völlig unklar.  ● Die erste Hälfte des 20. Jh. ist das „dunkle Zeitalter“ des Cannabis, in dem das Fors chungsinteresse erlahmte. [...]

Lire la suite

A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects, G. Morrison et al., , 2019

A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. G. Morrison, J. Crockett, G. Blakey, K. Sommerville Clinical Pharmacology in Drug Development, 2019, PMID : 30791225, DOI : 10.1002/cpdd.665 Abstract GW Pharmaceuticals' formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valproate are commonly used antiepileptic drugs. This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial investigated the impact of cannabidiol on steady-state pharmacokinetics of clobazam (and N-desmethylclobazam), stiripentol, and valproate; [...]

Lire la suite

Cannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System, P. Schonhofen et al., 2018.

Cannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System. Patricia Schonhofen, Ivi Juliana Bristot, José Alexandre Crippa, Jaime Eduardo Cecilio Hallak, Antonio Waldo Zuardi, Richard B. Parsons, Fabio Klamt CNS Drugs, 2018, 32 (Suppl 1), 1-16 https///doi.org/10.1007/s40263-018-0550-4 Abstract : The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components-cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes-are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor cell fate, neural [...]

Lire la suite

Qu’est-ce que le cannabinol (CBN) ? Le Cannabiste.com, 2019

Qu’est-ce que le cannabinol ? Les CBN est le Cannabinoïde responsable d’un meilleur sommeil Aujourd’hui , les capacités de développement et de recherche dans le secteur du cannabis reconnaisse que le facteur responsable du sommeil est le cannabinoïde communément appelé le CBN. Il vous reste quelques fleurs de canna dans une vieille boite ? Certes, il se pourrait qu’il soit beaucoup moins fort en THC. Mais il a de forte chance que votre contenu est chargé en CBN  Qu’est ce que le CBN  ? Le CBN se forme à partir du THC ” rance ” ou ” pas frais ”. Il a des avantages [...]

Lire la suite

Striking lung cancer response to self-administration of cannabidiol: A case report and literature review, Josep Sulé-Suso et al., 2019

Striking lung cancer response to self-administration of cannabidiol : A case report and literature review Josep Sulé-Suso, Nick A Watson, Daniel G van Pittius, Apurna Jegannathen SAGE Open Medical Case Reports, 2019, 7, 1-4.   Abstract : In spite of new drugs, lung cancer is associated with a very poor prognosis. While targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow-up. Thus, new drugs or reevaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both in vitro and in vivo is being carried [...]

Lire la suite

The Anti-Inflammatory Properties of Terpenoids from Cannabis, Ruth Gallily et al., 2018

The Anti-Inflammatory Properties of Terpenoids from Cannabis Ruth Gallily, Zhannah Yekhtin, and Lumı´r Ondrˇej Hanusˇ Cannabis and Cannabinoid Research, 3, 1, 2018, 282-290. Doi : 10.1089/can.2018.0014   Abstract : Introduction : Cannabinoids are well known to have anti-inflammatory effects in mammalians; however, the Cannabis plant also contains other compounds such as terpenoids, whose biological effects have not yet been characterized. The aim of this study was to compare the anti-inflammatory properties of terpenoids with those of cannabidiol (CBD). Materials and Methods : Essential oils prepared from three monoecious nonpsychoactive chemotypes of Cannabis were analyzed for their terpenoid content and subsequently studied pharmacologically for their anti-inflammatory properties in [...]

Lire la suite

How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review, Eva Hoch et al., 2019

How effective and safe is medical cannabis as a treatment of mental disorders ? A systematic review Eva Hoch,· Dominik Niemann, · Rupert von Keller, · Miriam Schneider, · Chris M. Friemel, · Ulrich W. Preuss ,·Alkomiet Hasan, · Oliver Pogarell European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi.org/10.1007/s00406-019-00984-4   Abstract : We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general [...]

Lire la suite

Medicinal Properties of Cannabis, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain : An Update on Current Evidence and Cannabis Science, E.P. Baron, 2018

Medicinal Properties of Cannabis, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain : An Update on Current Evidence and Cannabis Science, Eric P. BARON Headache, July/August 2018, 1139-1186.   Background.—Comprehensive literature reviews of historical perspectives and evidence supporting cannabis/ cannabinoids in the treatment of pain, including migraine and headache, with associated neurobiological mechanisms of pain modulation have been well described. Most of the existing literature reports on the cannabinoids Δ9- tetrahydrocannabinol (THC) and cannabidiol (CBD), or cannabis in general. There are many cannabis strains that vary widely in the composition of cannabinoids, terpenes, flavonoids, and other compounds. These components work [...]

Lire la suite

Cannabis – from cultivar to chemovar, A. Hazekamp and J. T. Fischedick, 2012

Cannabis - from cultivar to chemovar A. Hazekamp and J. T. Fischedick Drug Testing and Analysis, 2012, (wileyonlinelibrary.com) DOI 10.1002/dta.407, Copyright © 2012 John Wiley & Sons, Ltd.   Abstract : The medicinal use of Cannabis is increasing as countries worldwide are setting up official programs to provide patients with access to safe sources of medicinal-grade Cannabis. An important question that remains to be answered is which of the many varieties of Cannabis should be made available for medicinal use. Drug varieties of Cannabis are commonly distinguished through the use of popular names, with a major distinction being made between Indica and Sativa types. Although more than [...]

Lire la suite

The Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury, Lital MAJID et al., 2018

The Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury Lital MAJID, Sami HEYMAN, Merav ELGALI ... Esther SHOHAMI et al. Journal of Neurotrauma, Nov 2018, 36, 1-11 DOI: 10.1089/neu.2018.6063   Abstract : Cannabis is one of the most widely used plant drugs in the world today. In spite of the large number of scientific reports on medical marijuana, there still exists much controversy surrounding its use and the potential for abuse due to the undesirable psychotropic effects. However, recent developments in medicinal chemistry of novel non-psychoactive synthetic cannabinoids have indicated that it is possible to separate some of the therapeutic effects [...]

Lire la suite